Vera Therapeutics (VERA) director awarded 17,084-share stock option

(Neutral)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics, Inc. reported that director James R. Meyers received a stock option grant. The award covers options to buy 17,084 shares of Class A Common Stock at an exercise price of $34.35 per share, expiring on May 20, 2036.

The option vests in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholder meeting, as long as Meyers remains in continuous service. It will also vest in full upon a change in control if he continues in service through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Meyers James R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,084	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 17,084 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option shares granted: 17,084 shares Exercise price: $34.35 per share Shares underlying option post-grant: 17,084 shares +1 more

4 metrics

Option shares granted 17,084 shares Stock option grant to director on May 21, 2026

Exercise price $34.35 per share Exercise price of stock option

Shares underlying option post-grant 17,084 shares Total derivative holdings following transaction

Option expiration date May 20, 2036 Final date to exercise the option

Key Terms

Stock Option (right to buy), Class A Common Stock, change in control, continuous service

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

change in control financial

"shares will vest in full upon a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/26/2026 - 04:20 PM Accepted by SEC EDGAR 05/26/2026 - 04:19 PM

FAQ

What insider transaction did Vera Therapeutics (VERA) report for James R. Meyers?

Vera Therapeutics reported a stock option grant to director James R. Meyers. He received options to buy 17,084 shares of Class A Common Stock as a compensation-related award, not an open-market share purchase or sale.

How many shares are covered by James R. Meyers’ new option at Vera Therapeutics (VERA)?

The new option granted to James R. Meyers covers 17,084 shares of Class A Common Stock. This means he can buy up to 17,084 shares at the specified exercise price if and when the option is vested and exercised.

What is the exercise price of James R. Meyers’ stock option at Vera Therapeutics (VERA)?

The stock option granted to James R. Meyers has an exercise price of $34.35 per share. This is the fixed price he would pay per share to acquire Class A Common Stock if he exercises the option after it vests.

When does James R. Meyers’ Vera Therapeutics (VERA) option vest?

The option will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholder meeting, provided Meyers remains in continuous service through the applicable vesting date.

What happens to James R. Meyers’ option if Vera Therapeutics (VERA) undergoes a change in control?

If Vera Therapeutics undergoes a change in control, the option will vest in full at that time. This accelerated vesting applies as long as James R. Meyers remains in continuous service through the date of the change in control event.

When does James R. Meyers’ Vera Therapeutics (VERA) stock option expire?

The stock option granted to James R. Meyers expires on May 20, 2036. After that expiration date, he would no longer be able to exercise the option to purchase any shares, regardless of whether it was vested previously.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyers James R

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$34.35	05/21/2026		A		17,084		⁽¹⁾	05/20/2036	Class A Common Stock	17,084	$0	17,084	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

	/s/ Joseph R. Young, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR